Role of FBXO45 in Diffuse Large B Cell Lymphoma Pathogenesis
FBXO45 在弥漫性大 B 细胞淋巴瘤发病机制中的作用
基本信息
- 批准号:10412096
- 负责人:
- 金额:$ 2.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-03 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:3q29AffinityAffinity ChromatographyB cell differentiationB-Cell DevelopmentB-Cell LymphomasB-Lymphocyte SubsetsB-LymphocytesBCL2 geneBCL6 geneBiochemicalBiologicalBiological ProcessBirthCancer EtiologyCell Differentiation processCell LineCell physiologyCellsCellular biologyCessation of lifeCharacteristicsClustered Regularly Interspaced Short Palindromic RepeatsCommunitiesComplementConstitutionalCullin ProteinsDataDevelopmentEventF Box DomainFamilyGene TargetingGenesGeneticGenomicsGrowthGuanine Nucleotide Exchange FactorsHourHumanKnock-inKnock-outLymphomaLymphomagenesisMS4A1 geneMalignant NeoplasmsMediatingMolecularMolecular Biology TechniquesMusMutagenesisNeoplasmsOncogenicPathogenesisPharmacologyPlayProteolysisProteomicsRNARNA InterferenceRecurrenceResearchResourcesRoleSamplingStructure of germinal center of lymph nodeTamoxifenTestingTimeTransgenic MiceTumor Suppressor GenesTumor Suppressor ProteinsTumorigenicityUbiquitin-mediated Proteolysis PathwayUpdateXenograft Modelcohortgenome sequencingin vivoinsightlarge cell Diffuse non-Hodgkin&aposs lymphomamembermouse modelnovelnovel therapeutic interventionprognosticproteogenomicsscreeningsmall hairpin RNAtandem mass spectrometrytargeted treatmenttreatment strategyubiquitin ligaseubiquitin-protein ligasewhole genome
项目摘要
PROJECT SUMMARY
THE ROLE OF FBXO45 IN DIFFUSE LARGE B-CELL LYMPHOMA PATHOGENESIS
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and represents the
most common form of malignant lymphoma in the western hemisphere. The biologic events
underlying the pathogenesis of DLBCL are not completely understood. We have recently
identified functional inactivation of FBXO45, an E3 ubiquitin ligase in DLBCL. In this
application, we will utilize transgenic mouse models to explore the biological roles for
FBXO45 in B-cell differentiation and lymphomagenesis. Further, we will employ
biochemical and molecular biology techniques to better understand the role FBXO45 in the
pathogenesis of DLBCL. Accordingly, we propose in the first aim of this application to utilize
newly created transgenic mouse models to functionally interrogate the role of FBXO45 in B-
cell development and lymphomagenesis. In the second aim, we will identify the global
cellular substrates of FBXO45 in B cell contexts. These studies will establish the role of
FBXO45 in the pathogenesis of DLBCL and establish the mechanisms by which its
deregulation contributes to DLBCL.
项目摘要
FBXO 45在人大B细胞淋巴瘤发病中的作用
弥漫性大B细胞淋巴瘤(DLBCL)是一种侵袭性淋巴瘤,代表了
西半球最常见的恶性淋巴瘤。生物事件
DLBCL的潜在发病机制尚未完全了解。我们最近
鉴定了FBXO 45的功能失活,FBXO 45是DLBCL中的E3泛素连接酶。在这
应用中,我们将利用转基因小鼠模型来探索生物学作用,
FBXO 45在B细胞分化和淋巴瘤发生中的作用此外,我们将采用
生物化学和分子生物学技术,以更好地了解FBXO 45在
DLBCL的发病机制。因此,我们在本申请的第一个目的中提出利用
新创建的转基因小鼠模型,以功能性地询问FBXO 45在B-
细胞发育和淋巴瘤发生。在第二个目标中,我们将确定全球
FBXO 45在B细胞环境中的细胞底物。这些研究将确定
FBXO 45在DLBCL发病机制中的作用,并建立其作用机制。
放松管制有助于DLBCL。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KOJO S. J. ELENITOBA-JOHNSON其他文献
KOJO S. J. ELENITOBA-JOHNSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KOJO S. J. ELENITOBA-JOHNSON', 18)}}的其他基金
Role of FBXO45 in Diffuse Large B Cell Lymphoma Pathogenesis
FBXO45 在弥漫性大 B 细胞淋巴瘤发病机制中的作用
- 批准号:
10655478 - 财政年份:2022
- 资助金额:
$ 2.49万 - 项目类别:
Role of FBXO45 in Diffuse Large B Cell Lymphoma Pathogenesis
FBXO45 在弥漫性大 B 细胞淋巴瘤发病机制中的作用
- 批准号:
10703746 - 财政年份:2022
- 资助金额:
$ 2.49万 - 项目类别:
Role of FBXO45 in Diffuse Large B Cell Lymphoma Pathogenesis
FBXO45 在弥漫性大 B 细胞淋巴瘤发病机制中的作用
- 批准号:
9817011 - 财政年份:2019
- 资助金额:
$ 2.49万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 2.49万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 2.49万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 2.49万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 2.49万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 2.49万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 2.49万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 2.49万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 2.49万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 2.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 2.49万 - 项目类别:
Collaborative Research and Development Grants